Tilidine is a prodrug, which, following oral administration, is converted to the active analgesic metabolite, nortilidine. Tilidine is indicated for the relief of acute, moderate to severe pain, and chronic cancer-related pain. Currently Tilidine is not available in China and will be introduced by China Aoxing to the China market.
Zhenjiang Yue, the CEO of CAXG, said: “We expect to launch this important and needed cancer pain medicine through CAXG’s integrated 500-person sales force in later 2008. Our mission is to bring multiple effective therapeutic options, including Oxycodone, Tilidine and other promising narcotic pain medicines in our pipeline, to help approximately 20 million cancer patients in China.”